share_log

Assembly Biosciences | 8-K: Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

Assembly Biosciences | 8-K: Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

Assembly Biosciences | 8-K:Assembly Biosciences公布2024年第三季度财务业绩和最新
美股SEC公告 ·  11/08 05:22

Moomoo AI 已提取核心信息

On November 7, 2024, Assembly Biosciences, Inc., a biotechnology company, announced its financial results for the third quarter ending September 30, 2024. The company reported a cash position of $95.0 million, which is projected to fund operations into the first quarter of 2026. Revenue from collaborative research was $6.8 million, attributed to the collaboration with Gilead Sciences, Inc. Research and development expenses increased to $13.5 million due to more candidates in development, while general and administrative expenses remained stable at $4.3 million. The net loss for the quarter was $9.6 million, or $1.51 per share, an improvement from the $14.4 million loss in the same period of 2023. Assembly Biosciences also highlighted progress in its clinical pipeline, including positive Phase 1a interim data for ABI-5366, a candidate for recurrent genital herpes, and the initiation of Phase 1b trials. The company expects to release interim data for two other candidates, ABI-4334 and ABI-5366, by the end of 2024 and the first half of 2025, respectively. Additionally, two more candidates, ABI-1179 and ABI-6250, are on track to enter clinical trials by the end of 2024.
On November 7, 2024, Assembly Biosciences, Inc., a biotechnology company, announced its financial results for the third quarter ending September 30, 2024. The company reported a cash position of $95.0 million, which is projected to fund operations into the first quarter of 2026. Revenue from collaborative research was $6.8 million, attributed to the collaboration with Gilead Sciences, Inc. Research and development expenses increased to $13.5 million due to more candidates in development, while general and administrative expenses remained stable at $4.3 million. The net loss for the quarter was $9.6 million, or $1.51 per share, an improvement from the $14.4 million loss in the same period of 2023. Assembly Biosciences also highlighted progress in its clinical pipeline, including positive Phase 1a interim data for ABI-5366, a candidate for recurrent genital herpes, and the initiation of Phase 1b trials. The company expects to release interim data for two other candidates, ABI-4334 and ABI-5366, by the end of 2024 and the first half of 2025, respectively. Additionally, two more candidates, ABI-1179 and ABI-6250, are on track to enter clinical trials by the end of 2024.
2024年11月7日,生物技术公司assembly biosciences宣布截至2024年9月30日的第三季度财务业绩。公司报告现金余额为$9500万,预计可资助至2026年第一季度的运营。来自合作研究的营业收入为$680万,归因于与吉利德科学公司的合作。由于开发候选人增加,研发费用增至$1350万,而一般和行政费用保持在$430万的稳定水平。本季度净亏损为$960万,每股亏损$1.51,较2023年同期的$1440万减小。assembly biosciences还强调了其临床管线的进展,包括治疗复发性生殖器疱疹候选药ABI-5366的积极1a期中期数据以及进行第10亿阶段试验的启动。公司预计将于2024年底和2025年上半年发布另外两个候选药ABI-4334和ABI-5366的中期数据。此外,另外两个候选药ABI-1179和ABI-6250已计划于2024年底进入临床试验。
2024年11月7日,生物技术公司assembly biosciences宣布截至2024年9月30日的第三季度财务业绩。公司报告现金余额为$9500万,预计可资助至2026年第一季度的运营。来自合作研究的营业收入为$680万,归因于与吉利德科学公司的合作。由于开发候选人增加,研发费用增至$1350万,而一般和行政费用保持在$430万的稳定水平。本季度净亏损为$960万,每股亏损$1.51,较2023年同期的$1440万减小。assembly biosciences还强调了其临床管线的进展,包括治疗复发性生殖器疱疹候选药ABI-5366的积极1a期中期数据以及进行第10亿阶段试验的启动。公司预计将于2024年底和2025年上半年发布另外两个候选药ABI-4334和ABI-5366的中期数据。此外,另外两个候选药ABI-1179和ABI-6250已计划于2024年底进入临床试验。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息